Login / Signup
First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence.
Susanne Hafner
Published in:
Signal transduction and targeted therapy (2021)
Keyphrases
</>
small cell lung cancer
tyrosine kinase
epidermal growth factor receptor
advanced non small cell lung cancer
study protocol
brain metastases
vascular endothelial growth factor
clinical trial
endothelial cells
phase iii
phase ii
randomized controlled trial
chronic myeloid leukemia
double blind